Document is current
Any future updates will be listed below
-
Authors
Miles, Linde A. https://orcid.org/0000-0003-3578-2842
Bowman, Robert L. https://orcid.org/0000-0002-8294-8748
Merlinsky, Tiffany R.
Csete, Isabelle S.
Ooi, Aik T.
Durruthy-Durruthy, Robert
Bowman, Michael
Famulare, Christopher
Patel, Minal A.
Mendez, Pedro
Ainali, Chrysanthi
Demaree, Benjamin https://orcid.org/0000-0003-2278-6633
Delley, Cyrille L.
Abate, Adam R.
Manivannan, Manimozhi
Sahu, Sombeet https://orcid.org/0000-0003-2514-2569
Goldberg, Aaron D.
Bolton, Kelly L.
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Rampal, Raajit
Carroll, Martin P.
Meyer, Sara E. https://orcid.org/0000-0003-2930-748X
Viny, Aaron D. https://orcid.org/0000-0001-7039-0110
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
- License Information
-
More Information
Article History
Received: 26 January 2020
Accepted: 11 August 2020
First Online: 28 October 2020
Competing interests
: L.A.M. and A.D.V. received travel support and honoraria from Mission Bio. A.T.O., R.D.-D., P.M., C.A., M.M., and S.S. are employed by Mission Bio and own equity in Mission Bio. A.R.A. is a cofounder and shareholder of Mission Bio. A.Z. has received honoraria from Illumina. M.P.C. has consulted for Janssen Pharmaceuticals. A.D.G. has served on advisory boards or as a consultant for AbbVie, Aptose, Celgene, Daiichi Sankyo, and Genentech, received research funding from AbbVie, ADC Therapeutics, Aprea, Aptose, AROG, Celularity, Daiichi Sankyo, and Pfizer, and received honoraria from Dava Oncology. R.R. has consulted for Constellation, Incyte, Celgene, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, Stemline, Galecto, Pharmessentia, and Abbvie, and received research support from Incyte, Stemline, and Constellation. A.D.V. is on the Editorial Advisory Board of Hematology News. R.L.L. is on the supervisory board of QIAGEN and is a scientific advisor to Mission Bio, Loxo (until February 2019), Imago, C4 Therapeutics, and Isoplexis. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Jubilant, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria from Roche, Lilly, and Amgen for invited lectures and from Celgene and Gilead for grant reviews. R.L.B., T.R.M., I.S.C., C.F., M.A.P., M.B., B.D., C.L.D., K.B., and S.E.M. disclose no competing interests.
